Mizolastine

Allergic conditions

Oral Allergic conditions Adult: 10 mg daily. Elderly: 10 mg daily.

Oral Allergic conditions Child: >12 yr: 10 mg daily.

Significant cardiac or hepatic disease; electrolyte imbalance, particularly hypokalaemia; known or suspected QT prolongation. Clinically significant bradycardia.

May impair ability to drive or operate machinery. Elderly. Pregnancy (avoid in 1st trimester) and lactation.

Not Classi

Antidepressants and anxiolytics may enhance sedative effect. Potent inhibitors of or substrates for the hepatic metabolism of mizolastine (e.g. cimetidine, ciclosporin, nifedipine) may alter its metabolism. Potentially Fatal: Increased risk of cardiac arrhythmias with drugs known to prolong the QT interval e.g. class I and III antiarryhthmics. Increased plasma concentrations with macrolide antibiotics and imidazole antifungals.

Dry mouth, diarrhoea, abdominal pain, nausea; transient drowsiness, headache, dizziness; anxiety and depression; raised liver enzymes: low neutrophil count; transient asthenia, increased appetite associated with wt gain; allergic reactions e.g. angioedema, generalised rash/urticaria, pruritus and hypotension; tachycardia, palpitations; vasovagal attack; arthralgia and myalgia. Potentially Fatal: Anaphylaxis.

Mizolastine, a non-sedating antihistamine, blocks histamine H1-receptors on effector cells of the GI tract, blood vessels and respiratory tract. It also has mast-cell stabilising properties.